Cargando…
Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin
The poor water solubility of apremilast (APR) is the main impediment to the penetration of the drug through the skin barrier. The objective of this study was to evaluate the permeability of APR in different solutions enriched with penetration promoters in ex vivo samples of human skin, and additiona...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147106/ https://www.ncbi.nlm.nih.gov/pubmed/35631597 http://dx.doi.org/10.3390/pharmaceutics14051011 |
_version_ | 1784716726539124736 |
---|---|
author | Sarango-Granda, Paulo Espinoza, Lupe Carolina Díaz-Garrido, Natalia Alvarado, Helen Rodríguez-Lagunas, María J. Baldomá, Laura Calpena, Ana |
author_facet | Sarango-Granda, Paulo Espinoza, Lupe Carolina Díaz-Garrido, Natalia Alvarado, Helen Rodríguez-Lagunas, María J. Baldomá, Laura Calpena, Ana |
author_sort | Sarango-Granda, Paulo |
collection | PubMed |
description | The poor water solubility of apremilast (APR) is the main impediment to the penetration of the drug through the skin barrier. The objective of this study was to evaluate the permeability of APR in different solutions enriched with penetration promoters in ex vivo samples of human skin, and additionally assess its tolerance in vivo. To this end, APR solutions with 5% promoter were developed, and the drug’s ability to penetrate human abdominal skin samples was evaluated; the coefficients of permeability, cumulated amounts permeated, and flow were some of the parameters evaluated; likewise, the in vitro and in vivo tolerance of the solutions was evaluated. The results obtained showed that the solutions containing squalene as a promoter improved the penetration of APR compared to the other promoters evaluated; in the same way, on an in vitro scale in HaCaT cells, the promoters were not toxic, finding a cell viability greater than 80% at the different dilutions evaluated. In the in vivo tests carried out with the solution that presented the best results (APR-Squalene solution), it was observed that it does not cause irritation or erythema on the skin after its colorimetric and histological evaluation of the dorsal region of rats after its application. Squalene becomes an excellent candidate to improve the permeability of the drug in the case of the development of a topical formulation; in addition, it was confirmed that this penetration enhancer is neither toxic nor irritating when in contact with the skin in in vivo tests. |
format | Online Article Text |
id | pubmed-9147106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91471062022-05-29 Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin Sarango-Granda, Paulo Espinoza, Lupe Carolina Díaz-Garrido, Natalia Alvarado, Helen Rodríguez-Lagunas, María J. Baldomá, Laura Calpena, Ana Pharmaceutics Article The poor water solubility of apremilast (APR) is the main impediment to the penetration of the drug through the skin barrier. The objective of this study was to evaluate the permeability of APR in different solutions enriched with penetration promoters in ex vivo samples of human skin, and additionally assess its tolerance in vivo. To this end, APR solutions with 5% promoter were developed, and the drug’s ability to penetrate human abdominal skin samples was evaluated; the coefficients of permeability, cumulated amounts permeated, and flow were some of the parameters evaluated; likewise, the in vitro and in vivo tolerance of the solutions was evaluated. The results obtained showed that the solutions containing squalene as a promoter improved the penetration of APR compared to the other promoters evaluated; in the same way, on an in vitro scale in HaCaT cells, the promoters were not toxic, finding a cell viability greater than 80% at the different dilutions evaluated. In the in vivo tests carried out with the solution that presented the best results (APR-Squalene solution), it was observed that it does not cause irritation or erythema on the skin after its colorimetric and histological evaluation of the dorsal region of rats after its application. Squalene becomes an excellent candidate to improve the permeability of the drug in the case of the development of a topical formulation; in addition, it was confirmed that this penetration enhancer is neither toxic nor irritating when in contact with the skin in in vivo tests. MDPI 2022-05-07 /pmc/articles/PMC9147106/ /pubmed/35631597 http://dx.doi.org/10.3390/pharmaceutics14051011 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sarango-Granda, Paulo Espinoza, Lupe Carolina Díaz-Garrido, Natalia Alvarado, Helen Rodríguez-Lagunas, María J. Baldomá, Laura Calpena, Ana Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title | Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title_full | Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title_fullStr | Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title_full_unstemmed | Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title_short | Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin |
title_sort | effect of penetration enhancers and safety on the transdermal delivery of apremilast in skin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147106/ https://www.ncbi.nlm.nih.gov/pubmed/35631597 http://dx.doi.org/10.3390/pharmaceutics14051011 |
work_keys_str_mv | AT sarangograndapaulo effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT espinozalupecarolina effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT diazgarridonatalia effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT alvaradohelen effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT rodriguezlagunasmariaj effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT baldomalaura effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin AT calpenaana effectofpenetrationenhancersandsafetyonthetransdermaldeliveryofapremilastinskin |